Citations

Clear

8 citation(s) found for "Smith, Christopher".

Neurological Examination Findings in Autistic Adults (P2.176)
Woodruff, Bryan K. , Hentz, Joseph G. , Duffy, Amy, Pollard, Elena L., Smith, Christopher, Geda, Yonas E.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.p2.176 Get It

Comparison of Office Mental Status Examinations to Screen Cognitive Performance in Adults with Autism Spectrum Disorders (P6.202)
Woodruff, Bryan K. , Hentz, Joseph G. , Smith, Christopher J. , Geda, Yonas V., Locke, Dona E.C.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.p6.202 Get It

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer
Engstrom, Lars D. , Aranda, Ruth , Waters, Laura , Moya, Krystal , Bowcut, Vickie , Vegar, Laura , Trinh, David , Hebbert, Allan , Smith, Christopher R. , Kulyk, Svitlana , Lawson, J. David , He, Leo , Hover, Laura D. , Hallin, Jill , Vanderpool, Darin , Briere, David M. , Blaj, Alice , Arbour, Kathryn C. , Jänne, Pasi A. , Papadopoulos, Kyriakos P. , Henry, Jason T. , Leventakos, Konstantinos , Christensen, James G. , Shazer, Ronald , Olson, Peter , Fernandez-Banet, Julio , Hallin, Jill , Vanderpool, Darin , Briere, David M , Blaj, Alice , Marx, Matthew A , Rodon, Jordi , Offin, Michael , Arbour, Kathryn C , Johnson, Melissa L , Kwiatkowski, David J. , Jänne, Pasi A , Haddox, Candace L , Papadopoulos, Kyriakos P , Henry, Jason T , Leventakos, Konstantinos , Christensen, James G , Shazer, Ronald , Olson, Peter , Johnson, Melissa L. , Haddox, Candace L.

Mayo Clinic

Cancer Discovery | August 8, 2023 | Volume: 13 | Issue: 11 | Pages: 2412-2431

10.1158/2159-8290.cd-23-0669 | PMID 37552839 Get It

Abstract Previous studies implicated protein arginine methyltransferase 5 (PRMT5) as a synthetic lethal target for MTAP-deleted (MTAP del) cancers; however, the pharmacologic characterization of small-molecule inhibitors that recapitulate the synthetic lethal phenotype has not been described. MRTX1719 selectively inhibited PRMT5 in the presence of MTA, which is elevated in MTAP del cancers, and inhibited PRMT5-dependent activity and cell viability with >70-fold selecti­vity in HCT116 MTAP del compared with HCT116 MTAP wild-type (WT) cells. MRTX1719 demonstrated dose-dependent antitumor activity and inhibition of PRMT5-dependent SDMA modification in MTAP del tumors. In contrast, MRTX1719 demonstrated minimal effects on SDMA and viability in MTAP WT tumor xenografts or hematopoietic cells. MRTX1719 demonstrated marked antitumor activity across a panel of xenograft models at well-tolerated doses. Early signs of clinical activity were observed including objective responses in patients with MTAP del melanoma, gallbladder adenocarcinoma, mesothelioma, non–small cell lung cancer, and malignant peripheral nerve sheath tumors from the phase I/II study. Significance: PRMT5 was identified as a synthetic lethal target for MTAP del cancers; however, previous PRMT5 inhibitors do not selectively target this genotype. The differentiated binding mode of MRTX1719 leverages the elevated MTA in MTAP del cancers and represents a promising therapy for the ∼10% of patients with cancer with this biomarker. See related commentary by Mulvaney, p. 2310. This article is featured in Selected Articles from This Issue, p. 2293
Sex-related brain connectivity correlates of compensation in adults with autism: insights into female protection
Walsh, Melissa , Pagni, Broc A. , Monahan, Leanna , Delaney, Shanna , Smith, Christopher J. , Baxter, Leslie C. , Braden, B. Blair , Walsh, Melissa J M , Pagni, Broc , Baxter, Leslie C.

Mayo Clinic

Cerebral Cortex | February 4, 2022 | Volume: 33 | Issue: 2 | Pages: 316-329

10.1093/cercor/bhac069 | PMID 35212373 Get It

AbstractThe male preponderance in autism spectrum disorder (ASD) led to the hypothesis that aspects of female biology are protective against ASD. Females with ASD (ASD-F) report more compensatory behaviors (i.e. “camouflaging”) to overcome ASD-related social differences, which may be a mechanism of protection. No studies have examined sex-related brain pathways supporting camouflaging in ASD-F, despite its potential to inform mechanisms underlying the ASD sex bias. We used functional connectivity (FC) to investigate “sex-atypical” and “sex-typical” FC patterns linked to camouflaging in adults with ASD and examined multimodal coherence of findings via structural connectometry. Exploratory associations with cognitive/emotional functioning examined the adaptive nature of FC patterns. We found (i) “sex-atypical” FC patterns linked to camouflaging in the hypothalamus and precuneus and (ii) “sex-typical” patterns in the right anterior cingulate and anterior parahippocampus. Higher hypothalamic FC with a limbic reward cluster also correlated with better cognitive control/emotion recognition. Structural connectometry validated FC results with consistent brain pathways/effect patterns implicated in ASD-F. In summary, “male-typical” and “female-typical” brain connectivity patterns support camouflaging in ASD-F in circuits implicated in reward, emotion, and memory retrieval. “Sex-atypical” results are consistent with fetal steroidogenic/neuroinflammatory hypotheses. However, female genetics/biology may contribute to “female-typical” patterns implicated in camouflaging.
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
Zakharia, Yousef , Rixe, Olivier , Drabick, Joseph J. , Shaheen, Montaser , Grossmann, Kenneth F. , Kolhe, Ravindra , Pacholczyk, Rafał , Sadek, Ramses , Tennant, Lucinda, Link, Charles J., Vahanian, Nicholas N., Brincks, Erik L. , Rossi, Gabriela R. , Munn, David H. , Milhem, Mohammed , McWilliams, Robert R. , Milhem, Mohammed M , Kolhe, Ravindra , Zakharia, Yousef , Smith, Christopher Matthew , Kennedy, Eugene Paul , Yu, Jiayi , Shen, Steven S.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | June 11, 2021 | Volume: 9 | Issue: 6 | Pages: e002057

10.1136/jitc-2020-002057 | PMID 34117113 Get It

Background The indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that, in cancer, is exploited by tumors to evade antitumor immunity. Indoximod is a small-molecule IDO pathway inhibitor that reverses the immunosuppressive effects of low tryptophan (Trp) and high kynurenine (Kyn) that result from IDO activity. In this study, indoximod was used in combination with a checkpoint inhibitor (CPI) pembrolizumab for the treatment for advanced melanoma. Methods Patients with advanced melanoma were enrolled in a single-arm phase II clinical trial evaluating the addition of indoximod to standard of care CPI approved for melanoma. Investigators administered their choice of CPI including pembrolizumab (P), nivolumab (N), or ipilimumab (I). Indoximod was administered continuously (1200 mg orally two times per day), with concurrent CPI dosed per US Food and Drug Administration (FDA)-approved label. Results Between July 2014 and July 2017, 131 patients were enrolled. (P) was used more frequently (n=114, 87%) per investigator’s choice. The efficacy evaluable population consisted of 89 patients from the phase II cohort with non-ocular melanoma who received indoximod combined with (P). The objective response rate (ORR) for the evaluable population was 51% with confirmed complete response of 20% and disease control rate of 70%. Median progression-free survival was 12.4 months (95% CI 6.4 to 24.9). The ORR for Programmed Death-Ligand 1 (PD-L1)-positive patients was 70% compared with 46% for PD-L1-negative patients. The combination was well tolerated, and side effects were similar to what was expected from single agent (P). Conclusion In this study, the combination of indoximod and (P) was well tolerated and showed antitumor efficacy that is worth further evaluation in selected patients with advanced melanoma.
Cross-Modality Comparisons Between Radiofrequency Ablation and Stereotactic Body Radiotherapy for Treatment of Hepatocellular Carcinoma: Limitations of the National Cancer Database
Olsen, Jeffrey R., Murphy, James D. , Hallemeier, Christopher L. , Huguet, F. , Apisarnthanarax, Smith , Huguet, Florence, Jabbour, Salma K. , Hallemeier, Christopher Leigh , Apisarnthanarax, Smith , Jabbour, Salma K

Mayo Clinic

Journal of Clinical Oncology | June 27, 2018 | Volume: 36 | Issue: 24 | Pages: 2564-2565

10.1200/jco.2018.78.2904 | PMID 29945521 Get It

Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer
Rodriguez‐Broadbent, Henry , Law, Philip , Sud, Amit , Palin, Kimmo , Tuupanen, Sari, Gylfe, Alexandra E., Hänninen, Ulrika A. , Cajuso, Tatiana , Tanskanen, Tomas , Kondelin, Johanna , Kaasinen, Eevi , Sarin, Antti‐Pekka , Rissanen, Harri , Knekt, Paul , Jousilahti, Pekka , Palotie, Aarno , Renkonen‐Sinisalo, Laura , Lepistö, Anna , Böhm, Jan , Mecklin, Jukka‐Pekka , Tassan, Nada Al , Palles, Claire , Martin, Lynn , Barclay, Ella, Farrington, Susan M. , Timofeeva, Maria , Wakil, Salma M. , Campbell, Harry , Idziaszczyk, Shelley, Kaplan, Richard , Kerr, Rachel , Kerr, David , Passarelli, Michael N. , Figueiredo, Jane C. , Buchanan, Daniel D. , Win, Aung Ko , Jenkins, Mark A. , Lindor, Noralane M. , Gallinger, Steven , Conti, David V. , Schumacher, Fredrick R. , Casey, Graham , Aaltonen, Lauri A. , Cheadle, Jeremy P. , Tomlinson, Ian , Dunlop, Malcolm G. , Houlston, Richard S. , Law, Philip J , Buchanan, Daniel D , Win, Aung K , Ripatti, Samuli , Eriksson, Johan G. , Pukkala, ­Eero , Salomaa, Veikko , Palotie, Aarno V. , Meyer, Brian F. , Smith, Christopher G. , Maughan, Tim , Hopper, John L. , Newcomb, Polly A. , Houlston, Richard S , Jenkins, Mark A , Kaplan, Richard , Kerr, Rachel , Palles, Claire , Conti, David V

Mayo Clinic

International Journal of Cancer | March 25, 2017 | Volume: 140 | Issue: 12 | Pages: 2701-2708

10.1002/ijc.30709 | PMID 28340513 Get It

While elevated blood cholesterol has been associated with an increased risk of colorectal cancer (CRC) in observational studies, causality is uncertain. Here we apply a Mendelian randomisation (MR) analysis to examine the potential causal relationship between lipid traits and CRC risk. We used single nucleotide polymorphisms (SNPs) associated with blood levels of total cholesterol (TC), triglyceride (TG), low‐density lipoprotein (LDL), and high‐density lipoprotein (HDL) as instrumental variables (IV). We calculated MR estimates for each risk factor with CRC using SNP‐CRC associations from 9,254 cases and 18,386 controls. Genetically predicted higher TC was associated with an elevated risk of CRC (odds ratios (OR) per unit SD increase = 1.46, 95% confidence interval [CI]: 1.20–1.79, p = 1.68 × 10−4). The pooled ORs for LDL, HDL, and TG were 1.05 (95% CI: 0.92–1.18, p = 0.49), 0.94 (95% CI: 0.84–1.05, p = 0.27), and 0.98 (95% CI: 0.85–1.12, p = 0.75) respectively. A genetic risk score for 3‐hydoxy‐3‐methylglutaryl‐coenzyme A reductase (HMGCR) to mimic the effects of statin therapy was associated with a reduced CRC risk (OR = 0.69, 95% CI: 0.49–0.99, p = 0.046). This study supports a causal relationship between higher levels of TC with CRC risk, and a further rationale for implementing public health strategies to reduce the prevalence of hyperlipidaemia.
Effects of 100 and 300 Units of Onabotulinum Toxin A on Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Phase II Randomized Clinical Trial
Crawford, E. David , Hirst, Kathryn , Kusek, John W., Donnell, Robert F., Kaplan, Steven A. , McVary, Kevin T. , Mynderse, Lance A. , Roehrborn, Claus G. , Smith, Christopher P. , Bruskewitz, Reginald C.

Mayo Clinic

Journal of Urology | July 27, 2011 | Volume: 186 | Issue: 3 | Pages: 965-970

10.1016/j.juro.2011.04.062 | PMID 21791356 Get It